© 2024 grapl ltd.
Risk Management Planning for Medicinal Products
Course Summary
Proactive risk management is a major component of good pharmacovigilance practice. This module sets out the principles of risk management planning and outlines regulatory requirements for risk management plans in regions that are major markets for medicinal products.
Purchasing Information
When you have completed your course order, Zenosis will finalise the setup of your course materials and contact you on the email address that you provide in your order. You can expect this process to be completed within one business day (using the UK business calendar) of completing your payment.
It is therefore essential that you use your real email address for your order, or indicate in the purchase notes the email address to be used for the course set-up, and check that any messages from Zenosis or grapl are not lost in your junk or spam folder.
You will have access to the course module(s) for a period of 180 days after your purchase is complete.
Detailed Course Information
Learning Objectives
• Explain important principles of risk management planning
• Give examples of risk minimisation activities
• Describe the selection of risk minimisation activities that are proportional to a product’s benefit/risk balance and do not impose undue burden on stakeholders
• Outline regulatory requirements for risk management plans in regions that are major markets for medicinal products
Who will benefit from this course
All staff working in medical, drug safety, or pharmacovigilance departments of pharmaceutical or biotechnology companies or contract research organisations should have access to this module. It will also be of value to healthcare professionals and regulatory authority personnel.
Module Outline
• Module overview – An outline of the module’s scope and objectives, and notes on terminology.
• Principles of risk management planning – In this session we set out principles of risk management planning as a major component of good pharmacovigilance practice. We discuss the modern emphasis on proactive risk management in addition to routine pharmacovigilance measures. We describe risk assessment factors important in safety specification, pharmacovigilance planning, and risk minimisation for a drug. We then focus on the selection, implementation, and evaluation of non-routine risk minimisation activities.
• Regulatory requirements for risk management plans – In this session we outline regulatory requirements for risk management plans in regions that are major markets for medicinal products: Europe, the USA, and (in a brief sketch) Japan. We describe the structure, main components, and submission requirements for EU Risk Management Plans and US Risk Evaluation and Mitigation Strategies, and we sketch notable aspects of risk management requirements in Japan.
• Assessment – Multiple-choice mastery assessment.
Roles
Drug Safety, Regulatory, Compliance, Manager
CPD Points
1.25
Region
Level
Introductory/Intermediate
Course Study Time
Approx 1.25 hours
USA, Europe, Other